{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:23:25Z","timestamp":1769822605193,"version":"3.49.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1080\/14712598.2024.2412650","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T12:15:14Z","timestamp":1727957714000},"page":"1199-1206","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["An evaluation of mirikizumab for the treatment of ulcerative colitis"],"prefix":"10.1080","volume":"24","author":[{"given":"Christopher","family":"White","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, St Thomas\u2019 Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St Thomas\u2019 Hospital, London, UK"},{"name":"School of Immunology and Microbial Sciences, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1102942"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0080"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-0963-7"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2022.08.039"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036584"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2371-5"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.10.039"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.035"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.06.043"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.15389"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312912"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.09.078"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01333-0"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad112"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.12.003"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1697227"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.01.001"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2018.12.002"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242598"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2023.2194632"},{"key":"e_1_3_5_25_1","unstructured":"OMVOH (mirikizumab) [package insert]. US food and drug administration. Eli Lilly & Company. Approved by FDA; 2023 Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761279s000lbl.pdf"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.123"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00466-4"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221130450"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.01.047"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0012"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.043"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000578"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae024"},{"key":"e_1_3_5_35_1","volume-title":"PK, efficacy and safety of mirikizumab as induction therapy in pediatric patients with moderately to severely active ulcerative colitis: results from the phase 2 SHINE-1 study [abstract no. 781]","author":"Kaplan J","year":"2023","unstructured":"Kaplan J, Bousvaros A, Turner D, editors. PK, efficacy and safety of mirikizumab as induction therapy in pediatric patients with moderately to severely active ulcerative colitis: results from the phase 2 SHINE-1 study [abstract no. 781]. Chicago, Illinois: Digestive Disease Week; 2023."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab185"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01281-z"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.738"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101587"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab143"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16609"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.016"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad050"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad070"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae004"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.050"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01909-1"},{"key":"e_1_3_5_48_1","unstructured":"Mirikizumab: European Medicines Agency. 2023 Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omvoh-epar-product-information_en.pdf"},{"key":"e_1_3_5_49_1","volume-title":"FDA approves Lilly\u2019s Omvoh\u2122 (mirikizumab-mrkz), a first-in-class treatment for adults with moderately to severely active ulcerative colitis","author":"Eli Lilly and Company","year":"2023","unstructured":"Eli Lilly and Company. FDA approves Lilly\u2019s Omvoh\u2122 (mirikizumab-mrkz), a first-in-class treatment for adults with moderately to severely active ulcerative colitis. Eli Lilly & Company [press release]; 2023. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac038"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0058"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0035"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otac002"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00427-7"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2024.2412650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T06:45:40Z","timestamp":1732862740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2024.2412650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1080\/14712598.2024.2412650"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2024.2412650","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}